Patent intelligence · US
US 8512258
Breath test device and method
Breath test device and method
Patent details — US 8512258
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 20, 2013
- Expiration
- Aug 15, 2033
- Applicant
- EXALENZ BIOSCIENCE LTD.
- Claims
- 28
- CPC classes
- A61K, A61K31/167, A61K49/00, A61K51/04
Quick answer
US 8512258 (Breath test device and method) is held by EXALENZ BIOSCIENCE LTD.. Status: granted. Granted Aug 20, 2013. Expires Aug 15, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- EXALENZ BIOSCIENCE LTD.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K31/167, A61K49/00, A61K51/04, A61K51/0402, A61K51/1206
More from EXALENZ BIOSCIENCE LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12414942
Compositions, methods, and systems for treating presbyopia
granted -
US 12180206
Aceclidine derivatives, compositions thereof and methods of use thereof
granted -
US 12128036
Compositions and methods for storage stable ophthalmic drugs
granted -
US 11648247
Compositions and methods for the treatment of presbyopia
granted -
US 11344538
Methods for the treatment of myopia
granted -
US 11273150
Compositions and methods for the treatment of presbyopia
granted -
US 11214569
Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof
granted -
US 11179328
Compositions and methods for the treatment of presbyopia
granted
Frequently asked questions
What is US patent 8512258?
US 8512258 (Breath test device and method) is held by EXALENZ BIOSCIENCE LTD.. Status: granted. Granted Aug 20, 2013. Expires Aug 15, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8512258?
EXALENZ BIOSCIENCE LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 8512258 expire?
Our index shows an expiration date of Aug 15, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.